Healthcare
Embla Medical hf.(OSSUY)
Live Price
Offline$3.82
+0.00% today
1Y Change
-4.63%
Window
Jun 25, 2025 β Jun 23, 2026
- Market Cap
- $1.63B
- Revenue Growth
- +9.0%
- EPS Growth
- +25.0%
- Dividend Yield
- 0.0%
Coverage: 254 bars Β· Jun 25, 2025 β Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Embla Medical hf. (OSSUY) is a Healthcare stock with a market cap of $1.63B and listed on OTC. The stock last traded around $3.81 and down 4.6% across the available one-year price window (Jun 25, 2025 β Jun 23, 2026). Baseline metrics include revenue growth of +9.0%, EPS growth of +25.0%, a dividend yield of 0.0%. What stands out right now is revenue +9.0%, EPS +25.0%, free cash flow +29.2% with operating margin 13.2% and ROIC 6.4%. Valuation is more restrained than many high-expectation growth names at P/E 18.9 and price/sales 1.7. Stock Foundry combines OSSUY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+9.0% vs +7.6% peer median
Operating Margin
Below sector median
+13.2% vs +19.4% peer median
P/E
Below sector median
18.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Feb 3, 2026 with revenue below estimates by -1.0%.
The operating story is still moving forward
Revenue is running at +9.0% and EPS at +25.0%, with operating margin around 13.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.6% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 3, 2026 | β | -10.9% | -10.9% | -20.5% |
2025 Oct 21, 2025 | β | +0.0% | +0.0% | +28.8% |
2025 Jul 22, 2025 | β | +0.0% | +0.0% | +0.0% |
Benchmark Edge
OSSUY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OSSUY
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OSSUY Max Drawdown
-34.58%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OSSUY and SPY.
Company Overview
Embla Medical hf.
Other OTC
Embla Medical hf is a global orthopaedics company, which engages in the design, development, manufacture, and sale of non-invasive orthopedic products. It operates through the following geographical segments: Americas; Europe Middle-East and Africa; and Americas and Aisa-Pacific. The company was founded by Γssur Kristinsson in 1971 and is headquartered in ReykjavΓk, Iceland.
- Leadership
- Sveinn Solvason
- IPO Date
- May 23, 2018
- Employees
- 4.0k
- Street Address
- Grjothals 1-5
- Mailing
- Reykjavik
- Region
- Reykjavik, IS
- Reporting Currency
- USD
- Investor Line
- 354 515 1300
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.9
- EV/EBITDA
- 11.1
- Price/Sales
- 1.7
- Price/Book
- 1.8
Growth
- Revenue
- +9.0%
- EPS
- +25.0%
- Free Cash Flow
- +29.2%
Profitability
- Gross Margin
- 58.9%
- Operating Margin
- 13.2%
- Net Margin
- 8.9%
- ROE
- 9.8%
- ROIC
- 6.4%
Balance Sheet
- Debt/Equity
- 0.61
- Current Ratio
- 1.21
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.